ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.04%
US Dollar vs MXN
18.1108
0.00%
Brent Oil
84.39
0.00%
Bitcoin
64,044.15
-0.31%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) Noticias

NRIX

Nurix Therapeutics (NRIX)

Nurix Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NRIX
FechaHoraFuenteTítuloSímboloCompañía
17/06/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
16/06/202404:30GlobeNewswire Inc.Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
13/06/202417:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
11/06/202415:06Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:NRIXNurix Therapeutics Inc
10/06/202406:00GlobeNewswire Inc.Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
03/06/202415:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NRIXNurix Therapeutics Inc
29/05/202406:00GlobeNewswire Inc.Nurix Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
28/05/202406:00GlobeNewswire Inc.Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical OfficerNASDAQ:NRIXNurix Therapeutics Inc
20/05/202415:00GlobeNewswire Inc.Nurix Therapeutics Announces Board Chair TransitionNASDAQ:NRIXNurix Therapeutics Inc
14/05/202409:00GlobeNewswire Inc.Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
07/05/202406:00GlobeNewswire Inc.Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
16/04/202417:21GlobeNewswire Inc.Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:NRIXNurix Therapeutics Inc
11/04/202422:38GlobeNewswire Inc.Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
11/04/202415:00GlobeNewswire Inc.Nurix Therapeutics Announces Proposed Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
10/04/202406:00GlobeNewswire Inc.Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
09/04/202412:15GlobeNewswire Inc.Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesNASDAQ:NRIXNurix Therapeutics Inc
09/04/202406:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6NASDAQ:NRIXNurix Therapeutics Inc
03/04/202406:00GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
02/04/202406:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesNASDAQ:NRIXNurix Therapeutics Inc
25/03/202406:00GlobeNewswire Inc.Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)NASDAQ:NRIXNurix Therapeutics Inc
20/03/202408:40GlobeNewswire Inc.Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) MeetingNASDAQ:NRIXNurix Therapeutics Inc
11/03/202406:00GlobeNewswire Inc.Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNASDAQ:NRIXNurix Therapeutics Inc
05/03/202415:30GlobeNewswire Inc.Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual MeetingNASDAQ:NRIXNurix Therapeutics Inc
15/02/202415:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NRIXNurix Therapeutics Inc
15/02/202415:00GlobeNewswire Inc.Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
14/02/202407:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRIXNurix Therapeutics Inc
01/02/202415:01GlobeNewswire Inc.Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 DegraderNASDAQ:NRIXNurix Therapeutics Inc
29/01/202415:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NRIXNurix Therapeutics Inc
16/01/202415:48Dow Jones NewsNurix Therapeutics Gets FDA Fast-Track Designation for NX-5948NASDAQ:NRIXNurix Therapeutics Inc
16/01/202415:01GlobeNewswire Inc.Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLLNASDAQ:NRIXNurix Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NRIX

Su Consulta Reciente

TG
TOTA
TotalEnergies
TG
A3KW36
Computershare
TG
A3LCXR
Banco Santander
BIT
UIJ169
Unicredit Bank
LSE
03NT
Rams Mtg.'a1'32
TSX
HPF.U
Harvest Energy Leaders P...
USOTC
DCHFF
Dachan Food Asia (PK)
TSXV
GRCC.P
Green Rise Capital
AMEX
EMNT
Pimco Enhanced Short Mat...
LSE
VUKE
Vanguardftse100
USOTC
RCMGS
RSE Collection (GM)
BIT
UC8ANP
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados